Screener
BridgeBio Pharma BBIO Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating lease liabilities | (1,852) | (1,470) |
| Deferred revenue | (2,379) | (2,571) |
| Other liabilities (2) | 4,617 | 2,945 |
| Net cash used in operating activities | (197,279) | (199,235) |
| Investing activities: | ||
| Purchases of marketable securities | (52,666) | — |
| Maturities of marketable securities | 10,000 | — |
| Payment for an intangible asset | — | (1,595) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's operating cash flow?
- BridgeBio Pharma (BBIO) reported operating cash flow of -$197.28M in Q1 2026.
- How has BridgeBio Pharma's operating cash flow changed year-over-year?
- BridgeBio Pharma's operating cash flow increased by 1.0% year-over-year, from -$199.24M to -$197.28M.
- What is the long-term trend for BridgeBio Pharma's operating cash flow?
- Over 3 years (2021 to 2025), BridgeBio Pharma's operating cash flow has grown at a -3.6% compound annual growth rate (CAGR), from -$497.93M to -$445.91M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about BridgeBio Pharma's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude